A high-dose recombinant influenza vaccine is more effective than the standard-dose vaccine among adults aged 50-64, according to a study published in the New England Journal of Medicine. Amber Hsiao, PhD, MPH, and colleagues compared the effectiveness of recombinant vaccines versus standard-dose vaccines against influenza-related outcomes in adults younger than 65.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Amber
Contact Amber, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack